Serum IL-33 as a diagnostic and prognostic marker in nonsmall cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2563-2566

  Hu, Liang An ^a   Fu, Yu ^a   Zhang, Dan Ni ^a   Zhang, Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Differential diagnosis; IL 33; Non small cell lung cancer; Prognosis

Indexed keywords

EID: 84880272452     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2563     Document Type: Article

References (18)

1. Bharti A, Ma PC, Salgia R (2007). Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom Rev, 26, 451-66.
2. Carriere V, Roussel L, Ortega N, et al (2007). IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A, 104,282-7.
3. Choi YS, Choi HJ, Min JK, et al (2009). Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood, 114, 3117-26.
4. Dinarello CA (1998). Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol, 16, 457-99.
5. Filipits M, Pirker R (2011). Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer, 74, 355-63.
6. Grunnet M, Sorensen JB (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76, 138-43.
7. Hoffman PC, Mauer AM ,Vokes EE (2000). Lung cancer. Lancet, 355, 479-85.
8. Indovina P, Marcelli E, Maranta P, Tarro G (2011). Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics, 2011, 726869.
9. Jemal A, Siegel R, Xu J, Ward E (2010).Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
10. Jovanovic I, Radosavljevic G, Mitrovic M, et al (2011). ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol, 41, 1902-12.
11. Küchler AM, Pollheimer J, Balogh J, et al (2008). Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol, 173, 1229-42.
12. Lee S, Kang J, Cho M, et al (2009). Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol, 34, 161-72.
13. López-González A, Ibeas Millán P, Cantos B, Provencio M (2012). Surveillance of resected non-small cell lung cancer. Clin Transl Oncol, 14, 721-5.
14. Oguz A, Unal D, Tasdemir A, et al (2013). Lack of any Association between Blood Groups and Lung Cancer, Independent of Histology. Asian Pac J Cancer Prev, 14, 453-6.
15. Schmitz J, Owyang A, Oldham E, et al (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptorrelated protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23, 479-90.
16. Srivastava S, Salim N, Robertson MJ (2010). Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem, 17, 3353-7.
17. Sun P, Ben Q, Tu S, et al (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601.
18. Tufman A, Huber RM (2010). Biological markers in lung cancer: A clinician's perspective. Cancer Biomark, 6, 123-35.